Smith & Nephew PLC

Smith & Nephew is a global medical devices business operating in the markets for advanced surgical devices comprising orthopaedic reconstruction and trauma, sports medicine and advanced wound management. Co.'s advanced medical products and services include: Orthopaedic Reconstruction and Trauma (joint replacement systems for knees and hips and products to help repair broken bones); Advanced Wound Management (treatment and prevention products for hard-to-heal wounds); and Sports Medicine (implants and enabling technologies for minimally invasive repair of the joint).
  • TickerSN.
  • ISINGB0009223206
  • ExchangeLondon Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited Kingdom

Analysts

Debbie Wang

Morningstar | Smith & Nephew Prepares for More M&A Activity

Smith & Nephew finished up 2018 not materially far off from our projections and we’re leaving our fair value unchanged for now. Similar to previous quarters, large joint implants continued to lag market growth in the fourth quarter. Accounting for roughly one third of total revenue, quarterly knees and hips rose 3% on an underlying basis, which was then whittled down to 1% by foreign exchange headwinds. The main bright spots came in the form of sports medicine, the Navio hand-held orthopedic robot, and the Pico single-use negative pressure wound therapy device. Unfortunately, these products we...

Debbie Wang

Smith & Nephew Prepares for More M&A Activity

Smith & Nephew finished up 2018 not materially far off from our projections and we’re leaving our fair value unchanged for now. Similar to previous quarters, large joint implants continued to lag market growth in the fourth quarter. Accounting for roughly one third of total revenue, quarterly knees and hips rose 3% on an underlying basis, which was then whittled down to 1% by foreign exchange headwinds. The main bright spots came in the form of sports medicine, the Navio hand-held orthopedic...

Smith & Nephew – Proxinvest Corporate Governance Rating ® : B

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

Debbie Wang

Morningstar | Smith & Nephew Prepares for More M&A Activity

Smith & Nephew finished up 2018 not materially far off from our projections and we’re leaving our fair value unchanged for now. Similar to previous quarters, large joint implants continued to lag market growth in the fourth quarter. Accounting for roughly one third of total revenue, quarterly knees and hips rose 3% on an underlying basis, which was then whittled down to 1% by foreign exchange headwinds. The main bright spots came in the form of sports medicine, the Navio hand-held orthopedic robot, and the Pico single-use negative pressure wound therapy device. Unfortunately, these products we...

Debbie Wang

Smith & Nephew Prepares for More M&A Activity

Smith & Nephew finished up 2018 not materially far off from our projections and we’re leaving our fair value unchanged for now. Similar to previous quarters, large joint implants continued to lag market growth in the fourth quarter. Accounting for roughly one third of total revenue, quarterly knees and hips rose 3% on an underlying basis, which was then whittled down to 1% by foreign exchange headwinds. The main bright spots came in the form of sports medicine, the Navio hand-held orthopedic...

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

With a more favourable environment, SMITH & NEPHEW PLC. improves to Slightly Positive

SMITH & NEPHEW PLC. (GB), a company active in the Medical Equipment industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date December 4, 2018, the closing price was GBp 1,460.50 and its potential was estimated at GBp 1,533.53.

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

Smith & Nephew – Proxinvest Corporate Governance Rating ® : B

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Proxy Report - 12/04/2018

Item 2: Approve the Remuneration Report. The structure is weighted more heavily towards short-term performance and alignment with performance has not been definitively demonstrated as qualitative criteria comprised 25% of the bonus and the committee had the discretion to make adjustments to the award.

Jérôme VINERIER

Analyse court terme - SMITH & NEPHEW PLC : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 1 342,00 p. La rupture du support à 1 150,00 p invaliderait cette tendance.

Jérôme VINERIER

Short term view - SMITH & NEPHEW PLC : The background trend is clearly bullish.

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at 1,342.00 p. Breaking below the support at 1,150.00 p would invalidate the trend.

Jérôme VINERIER

Analyse court terme - SMITH & NEPHEW PLC : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 1 251,00 p. La tendance baissière serait remise en cause au-dessus de 1 408,83 p.

Jérôme VINERIER

Short term view - SMITH & NEPHEW PLC : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at 1,251.00 p. The bearish trend would be challenged above 1,408.83 p.

Jérôme VINERIER

Analyse moyen terme - SMITH & NEPHEW PLC : Les cours baissent.

La tendance est incertaine. Les cours baissent, et il y a une possibilité d'accélération baissière. Une nouvelle tendance baissière tente de démarrer.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch